ArriVent BioPharma

Company snapshot

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medi

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ArriVent BioPharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ArriVent BioPharma.

1. Jun 8, 2026 Clinical update

   FURMO-006 — Phase 3

2. Jun 8, 2026 Clinical update

   FURMO-002 — Phase 1

3. Jun 5, 2026 Clinical update

   Furmonertinib — Phase 1

4. May 26, 2026 Clinical update

   furmonertinib 240 mg oral, daily — Phase 3

5. May 23, 2026 Clinical update

   Firmonertinib — Phase 3

View all clinical trial activity →

• What is ArriVent BioPharma?

  ArriVent BioPharma is a biotech organization headquartered in Newtown Square, USA. It trades on NYSE under ticker AVBP. Primary therapeutic focus areas include Metastatic Non-Small Cell Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Locally Ad

• Is ArriVent BioPharma publicly traded?

  Yes. ArriVent BioPharma is listed with ticker AVBP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ArriVent BioPharma develop or market?

  We link 4 drug profile(s) where ArriVent BioPharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/arrivent-biopharma#company-drugs.

• What are the latest developments for ArriVent BioPharma?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ArriVent BioPharma focus on?

  ArriVent BioPharma focuses on Metastatic Non-Small Cell Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.